|

| 产地 | France |
| 品牌 | AntibodySystem |
| 货号 | EHD12601 |
| 用途 | 仅用于科研 |
| 包装规格 | 100 μg |
| 纯度 | 0.95% |
| CAS编号 | |
| 是否进口 | 否 |
| 货号 | EHD12601 |
| 产品名称 | Recombinant Human VEGFA/VEGF165 Protein, C-His |
| 规格 | 100 μg |
| 价格 | 2880 |
| 状态 | Lyophilized |
| 储存缓冲液 | Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol. |
| 纯度 | >90% as determined by SDS-PAGE. |
| 应用 | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| 内毒水平 | Please contact with the lab for this information. |
| 表达系统 | Mammalian Cells |
| Accession | P15692 |
| 蛋白长度 | Ala27-Arg191 |
| 预测分子量 | 23.28 kDa |
| 稳定性与储存条件 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 重悬 | Reconstitute in sterile water for a stock solution. |
| 别名 | Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A |
| 物种 | Homo sapiens (Human) |
| 运输 | In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise. |
| 备注 | For research use only. |
VEGFA/VEGF165为生长因子蛋白,结合内皮受体传导信号,调控内皮增殖、脉管新生,机体多处组织均可合成。表达异常会造成脉管发育失衡,是内皮生长调控、组织微循环重塑方向常用研究靶点。
Q1:这款 VEGF165 蛋白表达系统与标签特点?
A:哺乳动物细胞表达,C 端 His 标签,分子量 23.28 kDa,SDS-PAGE 纯度>90%。
Q2:冻干 VEGFA 蛋白该怎样复溶?
A:采用无菌水复溶配制储备液,详细操作规范查看产品说明书。
Q3:储存条件与保质期要求?
A:短期 2~8℃存放,长期 - 20~-80℃保存,保质期 12 个月,严禁反复冻融。
Q4:蛋白用途以及使用限制?
A:可用于 WB、ELISA、免疫原制备,生物活性正在验证,仅用于科研使用。
前沿相关研究:
1.Pharmacovigilance-Based Identification and MechanisticExploration of Periodontitis-Related Drugs.PMID: 40957584.
2.Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six- Week Results from the Randomized Phase 3 PULSAR Trial. PMID:40876598.
3.Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial. PMID: 41534798
4.Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial. PMID: 41223900.
5.Real-World Experience With Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age- Related Macular Degeneration.PMID: 40915520.
6.Association of Anti-VEGF Therapy with Reported Ocular Adverse Events: A Global Pharmacovigilance Analysis. Ophthalmol Retina.PMID: 40902799.
7.Dioscin suppresses epithelial-mesenchymal transition in gastric cancer by upregulating Cx43 to inhibit the VEGFA/PI3K/Akt/mTOR pathway. PMID: 41353880.